

SANOFI-AVENTIS  
Form S-8  
December 23, 2004

---

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**Form S-8  
Registration Statement Under The Securities Act of 1933**

---

**Sanofi-Aventis**

(Exact name of Registrant as Specified in its Charter)

**Republic of France**  
(State or Other Jurisdiction of  
Incorporation or Organization)

**133529324**  
(I.R.S. Employer  
Identification No.)

**174 avenue de France**

**75013 Paris, France**  
(Address of Principal Executive  
Offices and Zip Code)

**Rhône-Poulenc S.A. 1994 Stock Option Plan**

**Rhône-Poulenc S.A. 1995 Stock Option Plan**

**Rhône-Poulenc S.A. 1997 Stock Option Plan**

**Rhône-Poulenc Rorer Inc. 1995 Equity Compensation Plan  
Rhône-Poulenc Rorer Inc. Amended and Restated Stock Plan**

**Hoechst AG 1999 Stock Option Plan**

**1999/2000 Aventis Stock Option Plans**

**Aventis 2000 Stock Option Plan**

**Aventis Stock Option Plan 2001**

**Aventis Stock Option Plan 2002**

**Aventis Stock Option Plan 2003**

(Full Titles of Plans)

---

**Joseph Haggerty**  
**Vice President and General Counsel**  
**Aventis Pharmaceuticals**

**300 Somerset Corporate Boulevard**  
**Bridgewater, New Jersey 08807**  
(Name and Address of Agent for Service)

**(908) 243-6000**

(Telephone Number, Including Area Code, of Agent for Service)

---

*Copies to:*

Edgar Filing: SANOFI-AVENTIS - Form S-8

**Dirk Oldenburg**  
**Senior Vice President and General Counsel**  
**Sanofi-Aventis**  
**174 avenue de France**  
**75013, Paris, France**  
**+ 33 1 53 77 40 00**

**David A. Katz**  
**Wachtell, Lipton, Rosen & Katz**  
**51 West 52nd Street**  
**New York, NY 10019**  
**(212) 403 1000**

**Calculation of Registration Fee**

<b>Title of Each Class of Securities to Be Registered</b>	<b>Amount to be Registered(1)</b>	<b>Proposed Maximum Offering Price Per Share(2)</b>	<b>Proposed Maximum Aggregate Offering Price(3)</b>	<b>Amount of Registration Fee(4)</b>
Sanofi-Aventis Ordinary Shares, nominal value 2	27,485,695	\$73.17	\$2,011,128,304	\$236,710

- (1) In each case the number of Sanofi-Aventis ordinary shares registered is based on the number of Aventis ordinary shares subject to outstanding options that are to be assumed by Sanofi-Aventis in the merger after adjustment to give effect to the merger exchange ratio of 27 Sanofi-Aventis ordinary shares for 23 Aventis ordinary shares. See Explanatory Note.
- (2) Calculated solely for the purposes of this offering under Rule 457(h) of the Securities Act of 1933, on the basis of the weighted average exercise price of the outstanding options to be assumed by Sanofi-Aventis in the merger, in each case after adjustment to give effect to the merger exchange ratio of 27 Sanofi-Aventis ordinary shares for 23 Aventis ordinary shares. See Explanatory Note. The adjusted exercise prices of the options have been converted into U.S. dollars on the basis of an exchange rate of 1 euro = \$1.3390, which was the Federal Reserve Bank of New York noon buying rate on December 22, 2004.
- (3) Calculated as the product of (x) the number of Sanofi-Aventis ordinary shares to be registered and (y) the weighted average exercise price of the options assumed.
- (4) Calculated as the product of (x) 0.0001177 and (y) the Proposed Maximum Aggregate Offering Price.

**EXPLANATORY NOTE**

On October 14, 2004, Sanofi-Aventis, a French *société anonyme*, and Aventis, a French *société anonyme* and subsidiary of Sanofi-Aventis in which Sanofi-Aventis holds 97.98% of the share capital, entered into an Agreement and Plan of Merger (the Merger Agreement), pursuant to which, among other things, Aventis will merge with and into Sanofi-Aventis (the Merger). As a result of the Merger, Sanofi-Aventis will continue as the surviving company, Aventis will be dissolved and the shareholders of Aventis (other than Aventis and Sanofi-Aventis) will receive 27 Sanofi-Aventis ordinary shares, nominal value 2 per share, for every 23 Aventis ordinary shares, nominal value 3.82 per share, that they hold (such ratio, the Merger Exchange Ratio). For legal purposes, the Merger Agreement provides that the Merger will be effective as of December 31, 2004.

On December 13, 2004, at a combined ordinary and extraordinary general meeting, the shareholders of Aventis voted to approve the Merger Agreement, the Merger and the dissolution of Aventis. On December 23, 2004, at an extraordinary general meeting, the shareholders of Sanofi-Aventis voted to approve the Merger Agreement and the Merger, as well as the increase in the share capital of Sanofi-Aventis and the issuance of the new Sanofi-Aventis ordinary shares to be issued in payment of the merger consideration.

The Merger Agreement expressly provides that Sanofi-Aventis, as successor to Aventis, agrees to be bound by Aventis's obligations under the Aventis subscription stock options. After the effective time of the Merger, the Aventis subscription stock options will entitle their holders to subscribe for Sanofi-Aventis ordinary shares instead of Aventis ordinary shares. The number of shares subject to the options and their exercise price will be adjusted to give effect to the Merger Exchange Ratio in the following manner:

the number of Sanofi-Aventis ordinary shares that each holder of Sanofi-Aventis options shall have the right to subscribe under any given subscription option plan shall equal that number of Aventis ordinary shares that could formerly have been subscribed under that plan multiplied by the Merger Exchange Ratio of 27/23 (or approximately 1.17391) applicable to shareholders, rounded down to the nearest whole number; and

the exercise price per Sanofi-Aventis ordinary share shall be equal to the exercise price per Aventis ordinary share divided by the Merger Exchange Ratio of 27/23 (or approximately 1.17391) applicable to shareholders, rounded down to the nearest whole euro centime;

with all other terms of exercise remaining unaltered.

At the extraordinary general meeting on December 31, 2004, Sanofi-Aventis shareholders voted to waive their preferential subscription rights with respect to the Sanofi-Aventis ordinary shares that will be issued on the exercise of the Aventis subscription stock options assumed by Sanofi-Aventis.

With respect to the purchase option plans issued by Aventis Inc. (formerly known as Rhône-Poulenc Rorer, Inc.) and Hoechst which provide for the purchase of Aventis shares, the Merger Agreement provides that Sanofi-Aventis shall cause the regulations of these plans to be amended to provide that, after the effective time of the Merger, holders of these purchase options may purchase Sanofi-Aventis shares after adjusting the purchase price and the number of shares subject to option by the Merger Exchange Ratio in the same manner as set forth above, with all other terms of exercise remaining unaltered.

Accordingly, this Registration Statement on Form S-8 registers the aggregate number of Sanofi-Aventis ordinary shares that may be issued on the exercise of outstanding Aventis subscription stock options held by U.S. holders. The following table sets forth (i) the date of the grant, (ii) the number of unexercised subscription stock options held by U.S. holders, (iii) the original exercise price of the options, (iv) the number of Sanofi-Aventis ordinary shares for which the options may be exercised after the Merger and which are being registered pursuant to this Registration Statement and (v) the adjusted exercise price:

---

Edgar Filing: SANOFI-AVENTIS - Form S-8

<b>Date of Original Grant</b>	<b>Number of Aventis ordinary shares subject to outstanding options held by U.S. holders</b>	<b>Original Exercise Price</b>	<b>Number of Sanofi-Aventis ordinary shares to be issued on exercise of options after the Merger and registered pursuant to this Registration Statement</b>	<b>Adjusted Exercise Price</b>
February 7, 1995	8,500	17.66	9,978	15.04
December 14, 1995	10,000	15.40	11,739	13.11
December 17, 1996	17,500	23.53	20,543	20.04
December 16, 1997	291,647	37.75	342,368	32.15
December 15, 1998	639,433	40.08	750,639	34.14
February 15, 1999	1,340,575	58.75	1,573,718	50.04
May 11, 2000	240,520	58.29	282,350	49.65
November 14, 2000	4,573,466	79.75	5,368,851	67.93
March 29, 2001	53,250	80.94	62,511	68.94
November 7, 2001	4,659,375	83.81	5,469,701	71.39
November 12, 2002	5,160,200	60.27	6,057,626	51.34
December 2, 2003	6,006,955	47.52	7,051,643	40.48
<b>Total/ wt. average</b>	<b>23,001,421</b>	<b>64.61</b>	<b>27,001,668</b>	<b>55.04</b>

This Registration Statement also registers the aggregate number of Sanofi-Aventis ordinary shares that may be purchased on the exercise of outstanding purchase stock options held by U.S. holders issued under the option plans of Aventis Inc. (formerly known as Rhône-Poulenc Rorer Inc.). The following table sets forth the same data as above with respect to these purchase options:

<b>Date of Original Grant</b>	<b>Number of Aventis ordinary shares subject to outstanding options held by U.S. holders</b>	<b>Original Exercise Price</b>	<b>Number of Sanofi-Aventis ordinary shares to be issued on exercise of options after the Merger and registered pursuant to this Registration Statement</b>	<b>Adjusted Exercise Price</b>
February 27, 1995	30,017	\$ 16.67	35,237	\$ 14.20
February 27, 1996	44,554	\$ 26.67	52,303	\$ 22.71

Edgar Filing: SANOFI-AVENTIS - Form S-8

February 20, 1997	64,546	\$ 30.68	75,771	\$ 26.13
<b>Total/wt average</b>	<b>139,117</b>	<b>\$ 26.37</b>	<b>163,311</b>	<b>\$ 22.46</b>

This Registration Statement also registers the aggregate number of Sanofi-Aventis ordinary shares that may be purchased on the exercise of outstanding purchase stock options held by U.S. holders issued under the option plans of Hoechst. The following table sets forth the same data as above with respect to these purchase options:

<b>Date of Original Grant</b>	<b>Number of Aventis ordinary shares subject to outstanding options held by U.S. holders</b>	<b>Original Exercise Price</b>	<b>Number of Sanofi-Aventis ordinary shares to be issued on exercise of options after the Merger and registered pursuant to this Registration Statement</b>	<b>Adjusted Exercise Price</b>
September 7, 1999	273,202	48.43	320,715	41.25

**PART I**

**INFORMATION REQUIRED IN THE PROSPECTUS**

**Item 1. Plan Information**

Omitted pursuant to the instructions and provisions of Form S-8.

**Item 2. Registrant Information and Employee Plan Annual Information**

Omitted pursuant to the instructions and provisions of Form S-8.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3. Incorporation of Documents by Reference**

This Registration Statement on Form S-8 hereby incorporates by reference the contents of the following reports of Sanofi-Aventis (the Registrant, formerly known as Sanofi-Synthelabo) filed with, or furnished to, the Securities and Exchange Commission (the Commission) pursuant to the Securities Exchange Act of 1934, as amended (the Exchange Act):

(a) The Annual Report on Form 20-F of the Registrant for the year ended December 31, 2003 (the Form 20-F) (Commission file No. 001-31368);

(b) The Reports on Form 6-K furnished by the Registrant (whether under the names Sanofi-Synthelabo or Sanofi-Aventis) to the Commission pursuant to Section 13(a) or 15(d) of the Exchange Act on the following dates: January 7, 2004, January 8, 2004, January 12, 2004, January 20, 2004, January 29, 2004, February 4, 2004, February 16, 2004, March 9, 2004, March 10, 2004, March 19, 2004, March 23, 2004, March 31, 2004, April 5, 2004, April 12, 2004, April 13, 2004, April 15, 2004, April 22, 2004, April 26, 2004, April 27, 2004, May 4, 2004, May 5, 2004, May 14, 2004, May 21, 2004, May 26, 2004, June 2, 2004, June 4, 2004, June 14, 2004, June 22, 2004, June 24, 2004, June 25, 2004, July 15, 2004 (two reports), July 21, 2004, July 29, 2004, August 2, 2004, August 9, 2004, August 12, 2004, August 13, 2004, August 19, 2004, August 24, 2004, August 31, 2004, September 7, 2004, September 14, 2004, September 16, 2004, September 17, 2004, September 22 (two reports), October 8, 2004 (report relating to Actonel® press release), October 14, 2004, November 5, 2004 (report relating to Taxotere® and Eloxatin® press releases); November 9, 2004; November 24, 2004, November 26, 2004 (report relating to press release regarding relocation of Aventis headquarters), November 30, 2004, December 9, 2004 (report relating to press release regarding U.S. intellectual property litigation); December 10, 2004; December 16, 2004 (report relating to financial calendar of Sanofi-Aventis); December 20, 2004; December 22, 2004 and December 23, 2004;

(c) The description of the Registrant's ordinary shares, nominal value \$2 per share, set forth under the captions A. Share Capital and B. Memorandum and Articles of Association in Item 10 of the Registrant's Registration Statement on Form 20-F (Commission file No. 001-31368), filed with the Commission on June 25, 2002 and the updated descriptions of the Registrant's ordinary shares and American depositary shares contained in the Post-Effective Amendment No. 3 to the Registration Statement on Form F-4 (Registration No. 333-112314) (the Form F-4) filed by the Registrant with the Commission on November 9, 2004, under the captions Description Of Sanofi-Aventis Ordinary Shares and Description Of Sanofi-Aventis American Depositary Shares, including any amendment or report filed for the purpose of updating such description; and

(d) All documents filed by the Registrant with the Commission pursuant to Sections 13(a), 13(c), 14, or 15(d) of the Exchange Act prior to the filing of a post-effective amendment indicating that all securities offered have been sold or that deregisters all securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date of filing of such documents reference. Statements contained in the foregoing documents incorporated by reference shall be deemed to be modified or superseded hereby to the extent that statements contained in the Prospectus, or in any subsequently filed documents that are amendments hereto or that are incorporated herein by reference, shall modify or replace such statements.

**Item 4. Description of Securities**

The information required by Item 4 is not applicable to this Registration Statement because the class of securities to be offered is registered under Section 12 of the Exchange Act.

**Item 5. Interests of named Experts and Counsel**

The information required by Item 5 is not applicable to this Registration Statement.

**Item 6. Indemnification of Directors and Officers**

The French Commercial Code prohibits provisions of *statuts* that limit the liability of directors. However, if a director is sued by a third party and ultimately prevails in the litigation on all counts, but is nevertheless required to bear attorneys' fees and costs, the company may reimburse those fees and costs pursuant to an indemnification arrangement with the director.

Under French law a company may purchase directors and officers' insurance for all or part of the members of its management. A French corporation is responsible to third parties for the consequences of the decisions of its board of directors. However, if those decisions qualify as mismanagement, the relevant member of the board of directors may have to fully or partly indemnify the company. Sanofi-Aventis has purchased insurance for all of its directors.

**Item 7. Exemption from Registration Claimed**

The information required by Item 7 is not applicable to this Registration Statement.

**Item 8. Exhibits**

- 4.1 Bylaws (*statuts*) of Sanofi-Aventis (incorporated herein by reference to Exhibit 3.1 of Post-Effective Amendment No. 2 to the Registration Statement on Form F-4 (Registration No. 333-112314) as filed by the Registrant with the Commission on October 15, 2004)
  - 4.2 Deposit Agreement (including the form of depositary receipt) between the Registrant and The Bank of New York, as depositary (incorporated herein by reference to Exhibit A to the Registration Statement on Form F-6 (Registration No. 333-116262) relating to American Depositary Shares, filed on June 8, 2004)
  - 4.3 Rules and Regulations for Aventis Stock Option Plan 2003
  - 4.4 Rules and Regulations for Aventis Stock Option Plan 2002
  - 4.5 Rules and Regulations for Aventis Stock Option Plan 2001
  - 4.6 Rules and Regulations for Aventis 2000 Stock Option Plan
  - 4.7 Description of the Aventis 1999/2000 Stock Option Plan
  - 4.8 Description of the Hoechst AG 1999 Stock Option Plan
  - 4.9 Forms of grant notice (Participation Forms) under the Hoechst AG 1999 Stock Option Plan
  - 4.10 Hoechst 1999 Stock Option Continuity Plan
  - 4.11 Rhône-Poulenc Rorer Inc. 1995 Equity Compensation Plan
-

## Edgar Filing: SANOFI-AVENTIS - Form S-8

4.12	Rhône-Poulenc Rorer Inc. Amended and Restated Stock Option Plan
4.13	Rhône-Poulenc S.A. 1994 Stock Option Plan (as authorized at the Ordinary and Extraordinary Meeting of Shareholders held on April 22, 1994)
4.14	Rhône-Poulenc S.A. 1995 Stock Option Plan (as authorized at the Ordinary and Extraordinary Meeting of Shareholders held on April 13, 1995)
4.15	Rhône-Poulenc S.A. 1997 Stock Option Plan (as authorized at the Ordinary and Extraordinary Meeting of Shareholders held on April 23, 1997)
4.16	Letter to Aventis option holders regarding the conversion of options into options on Sanofi-Aventis ordinary shares (Citigroup administered plans)
4.17	Letter to Aventis option holders regarding the conversion of options into options on Sanofi-Aventis ordinary shares (Citigroup administered plans)
4.18	Amendment to the rules of the stock option plans of Aventis Inc. (formerly known as Rhône-Poulenc Rorer Inc.)
4.19	Amendment to the Hoechst 1999 Stock Option Continuity Plan
5	Opinion of Patricia Kodyra regarding the validity of the Registrant's ordinary shares being registered
23.1	Consent of PricewaterhouseCoopers Audit
23.2	Consent of Ernst & Young Audit
23.3	Consent of Patricia Kodyra (included in Exhibit 5 above)
24	Power of Attorney

---

**Item 9. Undertakings**

(a) The undersigned Registrant hereby undertakes:

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement to include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement,

(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial *bona fide* offering thereof.

(3) To remove from registration by means of a post-effective amendment any of the securities being registered that remain unsold at the termination of the offering.

(b) The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be the initial *bona fide* offering thereof.

(c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers, and controlling persons of the Registrant pursuant to the provisions described in Item 6 of this Registration Statement, or otherwise, the registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer, or controlling person of the Registrant in the successful defense of any action, suit, or proceeding) is asserted by such director, officer, or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

---



Edgar Filing: SANOFI-AVENTIS - Form S-8

Signature	Title	Date
*	Director	December 23, 2004
Jean-René Fourtou		
*	Director	December 23, 2004
Serge Kampf		
*	Director	December 23, 2004
Igor Landau		
*	Director	December 23, 2004
Hubert Markl		
*	Director	December 23, 2004
Christian Mulliez		
*	Director	December 23, 2004
Lindsay Owen-Jones		
*	Director	December 23, 2004
Klaus Pohle		
	Director	
Hermann Scholl		
*	Director	December 23, 2004
Gérard Van Kemmel		
*	Director	December 23, 2004
Bruno Weymuller		
*	Authorized Representative in the United States of America	December 23, 2004
Timothy Rothwell		
*By: /s/ JEAN-CLAUDE LEROY		
Jean-Claude Leroy Attorney-in-fact		

## EXHIBIT INDEX

Exhibit No.	Description
4.1	Bylaws ( <i>statuts</i> ) of Sanofi-Aventis (incorporated herein by reference to Exhibit 3.1 of Post-Effective Amendment No. 2 to the Registration Statement on Form F-4 (Registration No. 333-112314) as filed by the Registrant with the Commission on October 15, 2004)
4.2	Deposit Agreement (including the form of depositary receipt) between the Registrant and The Bank of New York, as depositary (incorporated herein by reference to Exhibit A to the Registration Statement on Form F-6 (Registration No. 333-116262) relating to American Depositary Shares, filed on June 8, 2004)
4.3	Rules and Regulations for Aventis Stock Option Plan 2003
4.4	Rules and Regulations for Aventis Stock Option Plan 2002
4.5	Rules and Regulations for Aventis Stock Option Plan 2001
4.6	Rules and Regulations for Aventis 2000 Stock Option Plan
4.7	Description of the Aventis 1999/2000 Stock Option Plan
4.8	Description of the Hoechst AG 1999 Stock Option Plan
4.9	Forms of grant notice (Participation Forms) under the Hoechst AG 1999 Stock Option Plan
4.10	Hoechst 1999 Stock Option Continuity Plan
4.11	Rhône-Poulenc Rorer Inc. 1995 Equity Compensation Plan
4.12	Rhône-Poulenc Rorer Inc. Amended and Restated Stock Option Plan
4.13	Rhône-Poulenc S.A. 1994 Stock Option Plan (as authorized at the Ordinary and Extraordinary Meeting of Shareholders held on April 22, 1994)
4.14	Rhône-Poulenc S.A. 1995 Stock Option Plan (as authorized at the Ordinary and Extraordinary Meeting of Shareholders held on April 13, 1995)
4.15	Rhône-Poulenc S.A. 1997 Stock Option Plan (as authorized at the Ordinary and Extraordinary Meeting of Shareholders held on April 23, 1997)
4.16	Letter to Aventis option holders regarding the conversion of options into options on Sanofi-Aventis ordinary shares (Citigroup administered plans)

Edgar Filing: SANOFI-AVENTIS - Form S-8

<b>Exhibit No.</b>	<b>Description</b>
4.17	Letter to Aventis option holders regarding the conversion of options into options on Sanofi-Aventis ordinary shares (Citigroup administered plans)
4.18	Amendment to the rules of the stock option plans of Aventis Inc. (formerly known as Rhône-Poulenc Rorer Inc.)
4.19	Amendment to the Hoechst 1999 Stock Option Continuity Plan
5	Opinion of Patricia Kodyra regarding the validity of the Registrant's ordinary shares being registered
23.1	Consent of PricewaterhouseCoopers Audit
23.2	Consent of Ernst & Young Audit
23.3	Consent of Patricia Kodyra (included in Exhibit 5 above)
24	Power of Attorney